MRPharmS(IP), MSc, DPharm. Consultant respiratory pharmacist at University Hospitals of Leicester NHS Trust and honorary visiting professor, School of Pharmacy, DeMontfort University.
Examining the impact of sub-optimal inhaler technique and how healthcare professionals can support patients in optimising their technique.
The UK is experiencing an explosion of new drugs and inhaler devices being licensed for people with respiratory disease, increasing the complexity of prescribing for people with asthma or chronic obstructive pulmonary disease (COPD). The management of how these new products are introduced into clinical practice is important because they may vary in type of inhaler device and licensing. One product is DuoRespSpiromax, a cheaper “branded generic” of Symbicort Turbohaler, both containing
Make asthma SIMPLE for your patientsSubscription
This week saw the publication of the first national study of asthma deaths in the UK. Its findings provide some powerful statements for pharmacy. Anna Murphy explains.
Primum non nocereSubscription
Asthma: pathophysiology, causes and diagnosisSubscription
Asthma: long-term managementSubscription
Our concerns with Relvar ElliptaSubscription